Bioequivalence of two tablet formulations of atenolol after single oral administration in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 3, 2000, Pages 243-247

  Niopas, Ioannis ^a   Daftsios, Athanasios C ^b   Xanthakis, Ioannis ^b   Nikolaidis, Nicolaos ^b   Njau, Samuel N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Perrotis College   (Greece)

Author keywords

Atenolol; Azectol ; Bioavailability; Bioequivalence; CAS 29122 68 7; Clinical pharmacokinetics; Blockers

Indexed keywords

ATENOLOL; AZECTOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG EFFECT; DRUG FORMULATION; FEMALE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0034026888     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300193     Document Type: Article

References (8)

1. [1] Wadsworth, A. N., Murdoch, D., Brogden, R. N. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42, 468 (1991)
2. [2] Physicians' Desk Reference, 47th ed., p. 1129, Medical Economics Data (1993)
3. [3] Taeschner, W., Vozeh, S., in: Avery's Drug Treatment, 4th ed., T. M. Speight, N. H. G. Holford (eds.), p. 1639, Adis International, Auckland (1997)
4. [4] Fitzgerald, J. D., Ruffin, R., Smedstad, K. G. et al., Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur. J. Clin. Pharmacol. 13, 81 (1978)
5. [5] Mason, W. D., Winer, N., Kochak, G. et al., Kinetics and absolute bioavailability of atenolol, Clin. Pharmacol. Ther. 25, 408 (1979)
6. [6] Gibaldi, M., Perrier, D., Pharmacokinetics, 2nd ed., p. 409, Marcel Dekker, New York (1982)
7. [7] Chow, S. C., Liu, J. P., Design and Analysis of Bioavailability and Bioequivalence Studies, p. 163, Marcel Dekker, New York (1992)
8. [8] CPMP (Committee for Proprietary Medicinal Products) Working Party on the Efficacy of Medicinal Products 1991, Note for guidance: investigation of bioavailability and bioequivalence, Brussels (1991)